Noninvasive Brain Interfaces Threaten Neuralink
Neuralink
The real threat to Neuralink is not another implant, it is any headset or near brain device that gets good enough for useful control without putting a chip into the skull. Neuralink is building around very high signal quality, with thousands of electrodes placed directly in brain tissue through robot assisted surgery. That only makes sense if the performance gap stays large. If non surgical systems move from rough focus tracking into reliable cursor control, typing, and everyday device use, they could win on comfort, safety, and easier deployment across far more users.
-
Today the performance gap is still real. Neuralink records directly from brain tissue with over 1,000 electrodes, while Emotiv sells external EEG headsets with 5 or 14 channels, and Kernel Flow measures blood oxygen changes from a helmet sized research device rather than direct neural spikes.
-
Less invasive products can spread faster because they fit existing workflows. Synchron places its device through a blood vessel using catheter lab tools and avoids open brain surgery, while external EEG can be put on in minutes. That matters because hospitals, clinicians, and healthy users will tolerate setup friction very differently.
-
That creates a market ladder. External systems can own wellness, research, training, and lighter control tasks first. Minimally invasive systems can cover severe disability with lower procedure burden. Neuralink keeps the strongest case where patients need the highest bandwidth, fastest decoding, or eventual stimulation based therapies that simpler systems cannot match.
The market is heading toward segmentation by required performance, not a single winner. If non invasive and surface level systems keep improving, Neuralink will be pushed toward the hardest medical use cases first, then will need to prove that its extra bandwidth produces clearly better outcomes than easier alternatives.